Overlap Between Genomic and Immunohistological Immunotherapy Biomarkers
Maher Albitar, MD, SVP, Chief Medical Officer & Director, Research & Development, NeoGenomics
Date: August 29, 2017 at 2:50 PM
Location: Boston, MA
PPD-L1 expression as detected by immunohistochemistry remains the most extensively studied and used biomarker in immunotherapy. However new molecular biomarkers are emerging as potential predictor of response in immunotherapy. This includes tumor mutation burden (TMB), microsatellite instability (MSI), abnormalities in DNA repair genes and others. In addition, combining immunotherapy with targeted therapy is being considered at this time and selecting biomarkers that can predict the efficacy of such combination is becoming a significant unmet need. Data correlating genomic biomarkers with PD-L1 expression as detected by IHC will be presented and discussed.
Event Link: www.immuno-oncologysummit.com